Having trouble viewing this email? Click here to view it on our website

Aim at Melanoma
March 2011
2011 Fundraisers


St. Petersburg



Bloomington / Normal









Dallas / Fort Worth
San Antonio



Virginia Beach


To View Details & Register
Click Here >>

AIM Trivia Night

Saturday, April 2, 2011

Quincy, IL


To View Details
Click Here >>

Orchestra After Dark

Saturday, April 9, 2011

The Woodlands, TX


To View Details
Click Here >>


Ember Restaurant

Sunday, May 1, 2011

Orlando, FL


To View Details
Click Here >>

Monday, July 18, 2011

Plano, TX


To View Details & Register
Click Here >>

Int'l Melanoma Working Group (IMWG) Research Update

The IMWG will meet April 10-12 in Barcelona, Spain. Melanoma experts from the United States, Australia, and eight European countries will attend.


These experts will continue to focus on the launch of the IMWG Brain Metastases Tissue Bank and the first IMWG Clinical Trial, and to discuss important innovations in melanoma research.


To address a large unmet clinical and research need, the IMWG has drawn on its international network of top-tier researchers and embarked on two protocols using melanoma brain metastases. Collectively, these protocols will help...


~ characterize behavior of melanoma brain
   metastases compared with metastases
   in other body regions
~ serve as a model system to test emerging agents
~ provide molecular correlates of clinical activity 


The first protocol will collect pre-surgical brain metastases specimens from patients with operable brain metastases and proven BRAF V600E mutation and bank the specimens for further research.


The second protocol is a clinical procedure where many of these patients will be treated with the agent GSK2118436 both pre-operatively and post-operatively.


To further address resistance mechanisms, IMWG Investigators will continue to review pathways of resistance and the rationale for combination approaches to thwart resistance.


BioPharma will continue to provide updates on investigational agents in the pipeline.


To read more about the IMWG, click here >>

Presidential Citation Awarded by American Academy of Dermatology (AAD)


AIM is fortunate to have strong supporters like Donna Regen on our team!

In February, the AAD awarded a distinguished Presidential Citation to Donna in recognition of her efforts to educate the public about the dangers of tanning.

Donna's daughter Jaime died at 29 years young from melanoma. Thanks to Donna's hard work and diligence to ban indoor tanning for minors, Jaime's story is featured in the AAD's skin cancer public service advertising campaign.

To view the campaign, click here >>

2011 Melanoma Legislation

AIM has requested legislators across the country to introduce indoor tanning bills that restrict minors' access to tanning beds. Most bills seek to ban minors under 18 years of age.


To assist legislators, AIM and its supporters are providing statistics, offering public testimony, generating public awareness, and finding medical experts to testify.

Special thanks to Christy Hale, Cassie Maas, Christina Parker, Donna Regen, Henrietta (Hank) Saunders, California Society of Dermatology & Dermatologic Surgery, and Skin of Steel for their support!

In states convening this year but not introducing legislation, AIM is developing Melanoma Awareness Resolutions in hopes of introducing indoor tanning bills in 2012.


For more information on how you can help, contact: Samantha Guild

Patient & Caregiver Symposiums

View & Register for 2011 Symposiums >>


View 2010 Symposium Videos >>

Gift Donations

Support our efforts to find the CURE in memory/honor of someone special. 

Click Here >>



Shop Online

Shop GoodShop.com and a percentage of each purchase you make will be donated to support our efforts to find the CURE.

Patient Links
Join Our Facebook Online Support Community »
Patient & Caregiver Support»
Finding the Right Doctor»
What to Ask Your Doctor»
Frequently Asked Questions»
Patient & Caregiver Support»
Finding the Right Doctor»

Breaking News

GSK Starts Late-Stage Trials of Melanoma Drugs

British drugmaker GlaxoSmithKline (GSK) said it was starting two global late stage trials of drugs in advanced or metastatic melanoma in patients whose tumors have a particular gene mutation...

Read More»

Genentech Drug Shows Survival Benefit in Metastatic Melanoma

Genentech, a member of the Roche Group, announced that BRIM3, a Phase III clinical study of RG7204 (also know as PLX4032), showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma...

Read More»

Copyright © 2009 AIM at Melanoma Foundation. All rights reserved.

Privacy Policy    Unsubscribe    Signup a Friend
This message sent by AIM at Melanoma Foundation, 3040 Cutting Blvd., Richmond, CA 94804